Accelerate Diagnostics Stock Today
| AXDX Stock | USD 1.18 0.01 0.84% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Accelerate Diagnostics is trading at 1.18 as of the 17th of February 2025; that is 0.84 percent decrease since the beginning of the trading day. The stock's open price was 1.19. Accelerate Diagnostics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of February 2023 and ending today, the 17th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of November 1996 | Category Healthcare | Classification Health Care |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. The company has 25.04 M outstanding shares of which 463.58 K shares are presently shorted by private and institutional investors with about 9.79 trading days to cover. More on Accelerate Diagnostics
Moving against Accelerate Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Accelerate Stock Highlights
| President CEO | Jack Phillips | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAccelerate Diagnostics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Accelerate Diagnostics' financial leverage. It provides some insight into what part of Accelerate Diagnostics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accelerate Diagnostics (AXDX) is traded on NASDAQ Exchange in USA. It is located in 3950 South Country Club Road, Tucson, AZ, United States, 85714 and employs 134 people. Accelerate Diagnostics is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.55 M. Accelerate Diagnostics conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 25.04 M outstanding shares of which 463.58 K shares are presently shorted by private and institutional investors with about 9.79 trading days to cover.
Accelerate Diagnostics currently holds about 36.77 M in cash with (40.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45.
Check Accelerate Diagnostics Probability Of Bankruptcy
Ownership AllocationAccelerate Diagnostics holds a total of 25.04 Million outstanding shares. Accelerate Diagnostics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Accelerate Ownership Details
Accelerate Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-09-30 | 20.4 K | |
| Ironwood Wealth Management, Llc | 2024-12-31 | 20.3 K | |
| Millennium Management Llc | 2024-09-30 | 17 K | |
| Tudor Investment Corp Et Al | 2024-09-30 | 14.1 K | |
| Tejara Capital Ltd | 2024-12-31 | 13.1 K | |
| Citadel Advisors Llc | 2024-09-30 | 12.5 K | |
| Occudo Quantitative Strategies Lp | 2024-09-30 | 11.2 K | |
| Virtu Financial Llc | 2024-12-31 | 11.2 K | |
| Stratos Wealth Partners, Ltd | 2024-12-31 | 10.6 K | |
| Armistice Capital, Llc | 2024-09-30 | 2.1 M | |
| Hovey Youngman Associates Inc | 2024-12-31 | 1 M |
Accelerate Diagnostics Historical Income Statement
Accelerate Stock Against Markets
Accelerate Diagnostics Corporate Management
| Lawrence Mertz | Chief Officer | Profile | |
| Michael Bridge | Gen VP | Profile | |
| Laura Costa | VP Support | Profile | |
| Rita Boukamel | Senior EMEA | Profile | |
| Maya Gowri | Senior Operations | Profile |
Already Invested in Accelerate Diagnostics?
The danger of trading Accelerate Diagnostics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Accelerate Diagnostics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Accelerate Diagnostics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Accelerate Diagnostics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.